Table 2 Main outcomes in all patients and specific sub-groups
N | 2y PFS | p | 2y OS | p | 2y RI | p | 1y NRM | p | |
|---|---|---|---|---|---|---|---|---|---|
All | 18 | 45% | 66% | 38% | 14% | ||||
CR vs PR | 119 vs 79 | 55% vs 29% | 0.001 | 74% vs 55% | 0.03 | 27% vs 55% | < 0.001 | 13% vs 16% | 0.8 |
Haplo vs HLAid | 65 vs 133 | 63% vs 37% | 0.03 | 67% vs 63% | 0.6 | 24% vs 44% | 0.008 | 13% vs 15% | 0.9 |
CR Haplo vs | 37 | 75% | < 0.001a | 83% | 0.1 | 6% | < | 14% | 0.8 |
CR HLAid vs | 82 | 47% | 67% | 34% | 0.001a | 13% | |||
PR Haplo vs | 28 | 44% | 58% | 44% | 11% | ||||
PR HLAid | 51 | 22% | 54% | 60% | 18% |